Wells Fargo lowered the firm’s price target on Sabra Health Care (SBRA) to $20 from $21 and keeps an Overweight rating on the shares. The firm remains most constructive on Senior Housing as market data continues to signal strength in occupancy and rate, and broker contracts flag accelerated deal volumes.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA: